Shanghai Fosun Pharmaceutical (Group) Co (Shanghai Fosun Pharmaceutical (Group) Co) COGS-to-Revenue : 0.50 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue?

Shanghai Fosun Pharmaceutical (Group) Co's Cost of Goods Sold for the three months ended in Mar. 2024 was $705 Mil. Its Revenue for the three months ended in Mar. 2024 was $1,410 Mil.

Shanghai Fosun Pharmaceutical (Group) Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.50.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Shanghai Fosun Pharmaceutical (Group) Co's Gross Margin % for the three months ended in Mar. 2024 was 50.01%.

Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.40

0.45

0.52

0.53

0.52

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.49	0.51	0.55	0.54	0.50

Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue Calculation

Shanghai Fosun Pharmaceutical (Group) Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3024.468	/	5798.092
	=	0.52

Shanghai Fosun Pharmaceutical (Group) Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	705.09	/	1410.436
	=	0.50

Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Shanghai Fosun Pharmaceutical (Group) Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	705.09 / 1410.436
	=	50.01 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Shanghai Fosun Pharmaceutical (Group) Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co (Shanghai Fosun Pharmaceutical (Group) Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (OTCPK:SFOSF) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

02196:Hong Kong 08HH:Germany 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.